Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.71M$4.71Mderived−74.1% vs Q4 2017 Net Income-$11.68M-$11.68MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$12,648,000N/M Operating Cash Flowderived-$9,058,000N/M Free Cash Flowderived-$9,623,000N/M Margins · derivedOperating margin-268.7%−304.4 pt vs Q4 2017
Net margin-248.2%−289.5 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 18, 2019 · 77 d after period end